Immune Thrombocytopenia
Conditions
Interventions
None listed
Sponsors
Sobi
Eligibility
Inclusion criteria
Inclusion criteria: A subject must fulfill the following criteria in order to be included in the study: 1. Men or women =18 years of age 2. Formal diagnosis of primary ITP according to the ASH and ICR guidelines [14, 25] 3. Currently or have previously received a TPO-RA (either eltrombopag and/or romiplostim) in the last 12 months 4. Have been treated with a TPO-RA for a minimum of 3 months, with at least some of the treatment received in the last 12 months 5. Provide written informed consent 6. Ability to understand and respond in English; this does not need to be the participants’ first language or even their own language if they wish to use their own translator. If recruitment appears to be limited by this, then translations of the survey will be made. Further plans for deployment will also see the survey translated into Dutch, French, German, Italian and Spanish
Exclusion criteria
Exclusion criteria: The presence of any of the following will exclude a subject from inclusion in the study: 1. Known secondary immune thrombocytopenia 2. Foreseeable inability to cooperate with given instructions or study procedures 3. Inability to give consent
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Disease characteristics, patterns of treatment and satisfaction with therapy | — |
Primary
| Measure | Time frame |
|---|---|
| The relative preferences towards TPO-RA product characteristics | — |
Contacts
Public ContactSjoerd Visser-Peereboom
Sobi
Outcome results
None listed